Persistence of COVID-19 symptoms beyond 3 months and the delayed return to the usual state of health in Saudi Arabia: A cross-sectional study

Hend M Alkwai1, Amany M Khalifa2, Ahmed M Ahmed3, Alfatih M Alnajib3, Khaznah A Alshammari4, Muslama M Alrashidi4 and Hussain G Ahmed2

Abstract
A substantial number of COVID-19 survivors describe ongoing symptoms long after the acute phase. This so-called post-COVID-19 syndrome or long COVID occurs irrespective of initial disease severity.

Objectives: This cross-sectional study aims to describe and characterise the prevalence of persistent COVID-19 symptoms beyond three months and to evaluate the risk factors for the delayed return to the usual state of health.

Methods: An electronic survey was developed, piloted, and conducted during the first wave of the COVID-19 pandemic. The survey consisted of questions exploring socio-demographic data, comorbidities, COVID-19 disease (diagnosis, presenting symptoms, management, and persistent symptoms), and the return to the usual state of health. Participants were users of social media platforms. We received results from 746 respondents. One hundred thirty-six responses were excluded due to a self-diagnosis of COVID-19. Respondents reporting a COVID-19 diagnosis 3 months or more prior to the study (N = 213) were included in the analysis. Predictors of the delayed return to the usual state of health were identified by logistic regression.

Results: Three months or more after a COVID-19 diagnosis, almost half of the respondents, 109 (51.2%), had residual symptoms. The five most prevalent persistent symptoms were fatigue (13.6%), altered sense of smell (12.7%), muscle aches (10.3%), headache (9.9%), and body aches (8.5%). When questioned regarding the return to baseline health, 152 (71.4%) answered in the affirmative. The total number of chronic medical conditions was determined as a statistically significant predictor for the delayed return to the usual state of health.

Conclusion: Three months or more after acute COVID-19 infection, 5 out of 10 survivors experienced persistent symptoms, and 3 out of 10 reported a delayed return to baseline health. Considering the overall burden of COVID-19 disease, this can pose health and socio-economic challenges. Therefore, health systems need support in managing long COVID and improving long-term COVID-19 outcomes.

Keywords
SARS-CoV-2, long COVID, chronic COVID syndrome, post-acute sequelae of SARS-CoV-2 syndrome, PASC, post-COVID-19 syndrome

Introduction
As the COVID-19 pandemic continues to unfold, new insights appear and challenge previously acknowledged facts. One lately scrutinised aspect is the persistence of COVID-19 symptoms among some survivors, irrespective of initial disease severity. As of December 2021, COVID-19 has resulted in more than 289 million confirmed cases and more than five million deaths worldwide.1 Thereupon, the possibility of the persistence of debilitating symptoms...
among a proportion of those previously affected will likely pose additional stress on an already strained health care system with substantial societal and economic implications. The term ‘long COVID’ and the cognate term ‘long-hauler’ were initially coined by patients.\textsuperscript{2,3} Other terminologies used in the literature have included ‘chronic COVID syndrome’,\textsuperscript{4} ‘coronavirus long-hauler’,\textsuperscript{5} and ‘post-acute sequelae of SARS-CoV-2 infection’ (PASC).\textsuperscript{6} Due to the lack of a defined, globally accepted description and terminology for this condition, accurate diagnosis and treatment can be difficult.\textsuperscript{7} The United Kingdom’s National Institute for Health and Care Excellence (NICE) defines post-COVID-19 syndrome as ‘signs and symptoms that develop during or after an infection, consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis’.\textsuperscript{8} In this definition, long COVID overlaps with two categories, ‘ongoing symptomatic COVID-19’, which are symptoms lasting for 4 to 12 weeks; and ‘post-COVID-19 syndrome’, which are symptoms persisting beyond 12 weeks.\textsuperscript{9} Cognitive, mental, and physical health can be affected after COVID-19. This effect can be persistent or occur in an episodic fashion.\textsuperscript{10} Furthermore, these sequelae vary in frequency and severity.\textsuperscript{11,12} The exact aetiopathogenesis of the condition is unknown. Direct viral tissue damage, endothelial damage, dysregulation of immune responses, and maladaptation of ACE2-related pathways might contribute.\textsuperscript{13} Few studies have been published on the post-COVID-19 syndrome in Saudi Arabia. However, those were restricted to a specific patient population or reported shorter follow-up duration.\textsuperscript{14-16} Therefore, in this cross-sectional study, we aim to analyse the persistence of COVID-19 symptoms beyond 3 months or more of disease onset and return to the usual state of health in a mixed population of COVID-19 survivors. 

**Materials and methods**

This cross-sectional study was conducted in Saudi Arabia between 11 November 2020, and 11 December 2020, during the first wave of the pandemic (approximately 8 months after the first confirmed case of COVID-19 in the country, which was announced on 2 March 2020). Participants were users of social media platforms (Twitter and WhatsApp). They were invited online to participate in this study assessing long-term, persistent COVID-19 symptoms, and the return to the usual state of health. Inclusion criteria were an age of 18 years or above and a self-reported diagnosis of COVID-19 based on the assessment of a healthcare worker or a positive COVID-19 test. The exclusion criterion was a self-diagnosis of COVID-19 with no confirmatory testing.

An ad hoc web-based survey was developed in Arabic utilising SurveyMonkey (surveymonkey.com). Local studies on COVID-19\textsuperscript{17} and studies on long COVID\textsuperscript{18-20} were referred to during the development of the study instrument. Ultimately, the survey consisted of 19 open and close-ended questions divided into four parts. Part one explored socio-demographic data. Comorbidities were documented in part two using a checklist of 18 conditions (modified from the Charlson Comorbidity Index\textsuperscript{21} and other studies).\textsuperscript{19} In addition, respondents were given the option to document other comorbidities not listed. The number of comorbidities was then categorised as 0, 1, 2, or $\geq$ 3 comorbidities. COVID-19 diagnosis, presenting symptoms, management, and persistent symptoms were examined in part three. These were extrapolated from previous studies.\textsuperscript{17,19} Finally, participants were asked about the return to the usual state of health in part four. A pilot test involving 14 participants was conducted to confirm the clarity of questions and the reproducibility of answers. Based on the feedback, unclear questions were modified, and minor changes to the survey were made.

The study objectives were described to the participants, and written informed consent was obtained from all participants before the study. Anonymity was ensured as no identifying information was collected. No incentives were provided for answering the survey. The study was approved by the Research Ethics Committee at the University of Ha’il (Reference Number 00127/CM-UOH.04/20).

**Sample size**

The sample size (n = 663) was calculated using the formula: $n = \frac{Z_{\alpha/2}^2 \times p \times (1 - p)}{MOE^2}$, where $Z_{\alpha/2}$ is the critical value of the normal distribution at $\alpha/2$ (for a confidence level of 99%, $\alpha$ is 0.05, and the critical value is 1.96), N is the population size, p is the sample proportion (set at 50%), and MOE is the margin of error (set at 5%). The population size was estimated based on the total COVID-19 cases in Saudi Arabia as of 11 November 2020 (N = 352,200 cases). The electronic survey was online for a duration of 10 days to reach the calculated sample size. All responses received during this period were included. The NICE definition was used to define the duration of persistent symptoms.\textsuperscript{8} Thus, responses reporting a past COVID-19 diagnosis 3 months prior to the study are included in the analysis.

**Statistical analysis**

Data were entered and analysed using IBM SPSS Statistics (version 26). Means and standard deviations were used to describe the continuous data. Frequencies and percentages were used to describe categorical data. Statistical significance was set at $p < 0.05$ (two-tailed). Binomial logistic regression was performed to determine the effects of gender, age, the total number of chronic medical conditions, and the total number of initial symptoms on the likelihood that respondents do not return to their usual state of health. The linearity of the continuous variables with respect to the logit of the dependent variable was assessed via the Box-Tidwell
procedure. There were no significant outliers in the data. Model fit was assessed using the Hosmer and Lemeshow goodness of fit test. The model explained 5.1% (Nagelkerke $R^2$) of the variance in the return to the usual state of health and correctly classified 70.4% of cases.

Results

We received results from 746 respondents. The average time to complete the survey was around 4 min. One hundred thirty-six responses were excluded due to a self-diagnosis of COVID-19. Of the remaining 610 responses, only those from respondents reporting a COVID-19 diagnosis 3 months prior to the study ($N=213$) were included in the analysis for the post-COVID-19 syndrome. Of these, 162 (76.1%) were female, and 192 (90.1%) were less than 45 years of age. Table 1 summarises the demographic data and clinical characteristics of respondents.

At the time of diagnosis, 5 (2%) of the respondents were asymptomatic, 66 (31%) reported one to five symptoms, 70 (33%) had six to ten symptoms, and 72 (34%) had more than 10 symptoms. The most frequent presenting symptoms were headache 132 (62%), loss of smell and fatigue 130 (61%) each, body aches 117 (54.9%), and fever 115 (54%). COVID-19 diagnosis and management among respondents are summarised in Table 2.

More than 13 comorbid conditions were identified among the respondents, with 82 (38.5%) reporting one or more comorbid conditions. The number of comorbid conditions ($p<0.007$), and in particular being overweight ($p<0.021$), were significantly associated with developing persistent symptoms (see Table 1).

Table 1. Socio-demographic characteristics of the respondents.

| Age (years) | Total ($N=213$) (%) | Persistent COVID-19 symptoms beyond 3 months | $p$-value $\dagger$ |
|------------|------------------|------------------------------------------|------------------|
| 18–24 | 64 (30) | 36 (34.3) | 28 (25.9) | 0.252 |
| 25–34 | 82 (38.5) | 42 (40) | 40 (37) |
| 35–44 | 46 (21.6) | 20 (19) | 26 (24.1) |
| 45–54 | 14 (6.6) | 5 (4.8) | 9 (8.3) |
| 55–64 | 6 (2.8) | 1 (1) | 5 (4.6) |
| 65+ | 1 (0.5) | 1 (1) | 0 (0) |

| Marital status | Total ($N=213$) (%) | Persistent COVID-19 symptoms beyond 3 months | $p$-value $\dagger$ |
|----------------|------------------|------------------------------------------|------------------|
| Single | 79 (31.7) | 49 (46.7) | 30 (27.8) | 0.008 |
| Married | 125 (58.7) | 54 (51.4) | 71 (65.7) |
| Divorced/separated | 4 (1.9) | 2 (1.9) | 2 (1.9) |
| Widowed | 5 (2.3) | 0 (0) | 5 (4.6) |

| Education | Total ($N=213$) (%) | Persistent COVID-19 symptoms beyond 3 months | $p$-value $\dagger$ |
|-----------|------------------|------------------------------------------|------------------|
| Primary | 5 (2.3) | 3 (2.9) | 2 (1.9) | 0.021 |
| Secondary | 4 (1.9) | 0 (0) | 4 (3.7) |
| Tertiary | 204 (95.8) | 102 (97.1) | 102 (94.4) |

| Employment | Total ($N=213$) (%) | Persistent COVID-19 symptoms beyond 3 months | $p$-value $\dagger$ |
|------------|------------------|------------------------------------------|------------------|
| Student | 50 (23.5) | 31 (29.5) | 19 (17.6) | 0.004 |
| Governmental sector | 60 (28.1) | 29 (27.6) | 31 (28.7) |
| Private sector | 20 (9.4) | 11 (10.5) | 9 (8.3) |
| Homemaker/unemployed | 83 (39) | 34 (32.4) | 49 (45.4) |

| Monthly income (SAR*) | Total ($N=213$) (%) | Persistent COVID-19 symptoms beyond 3 months | $p$-value $\dagger$ |
|----------------------|------------------|------------------------------------------|------------------|
| <5000 | 60 (28.2) | 31 (29.5) | 29 (26.9) | 0.226 |
| 5000–10,000 | 55 (25.8) | 23 (21.9) | 32 (26.9) |
| >10,000–15,000 | 44 (20.7) | 18 (17.1) | 26 (24.1) |
| >15,000–20,000 | 22 (10.3) | 12 (11.4) | 10 (9.3) |
| >20,000–25,000 | 17 (8) | 10 (9.5) | 7 (6.5) |
| >25,000 | 15 (7) | 11 (10.5) | 4 (3.7) |

(Continued)
Table 1. COVID-19 diagnosis and management among respondents.

| Number of medical conditions | Total (N=213) (%) | Persistent COVID-19 symptoms beyond 3 months | p-value§ |
|------------------------------|------------------|-----------------------------------------------|----------|
|                              | No (N = 105) (%) | Yes (N = 108) (%)                             |          |
| 0                            | 131 (61.5)       | 78 (74.3)                                     | 53 (49.1)| 0.007 |
| 1                            | 52 (24.4)        | 19 (18.1)                                     | 33 (30.6)|          |
| 2                            | 18 (8.5)         | 4 (3.8)                                       | 14 (13)  |          |
| ⩾3                           | 12 (5.6)         | 4 (3.8)                                       | 8 (7.4)  |          |

Individual medical conditions

- Hypertension: 14 (6.6) no, 5 (4.8) yes, 9 (8.3) yes, p-value 0.220
- Diabetes: 8 (3.8) no, 4 (3.8) yes, 4 (3.7) yes, p-value 0.624
- Coronary artery disease: 1 (0.5) no, 1 (1) yes, 0 (0) yes, p-value 0.493
- Overweight: 32 (15) no, 10 (9.5) yes, 22 (20.4) yes, p-value 0.021
- Anxiety: 20 (9.4) no, 6 (5.7) yes, 14 (13) yes, p-value 0.056
- Depression: 10 (4.7) no, 2 (1.9) yes, 8 (7.4) yes, p-value 0.055
- Other mental health disorder: 4 (1.9) no, 0 (0) yes, 4 (3.7) yes, p-value 0.064
- Asthma: 25 (11.7) no, 9 (8.6) yes, 16 (14.8) yes, p-value 0.114
- Immunosuppressive condition: 2 (0.9) no, 0 (0) yes, 2 (1.9) yes, p-value 0.256
- Drug-induced immune suppression: 4 (1.9) no, 1 (1) yes, 3 (2.8) yes, p-value 0.321
- Chronic kidney disorder: 1 (0.5) no, 0 (0) yes, 1 (0.9) yes, p-value 0.507
- Chronic haematological disorder: 4 (1.9) no, 0 (0) yes, 4 (3.7) yes, p-value 0.064
- Hypothyroidism: 4 (1.9) no, 2 (1.9) yes, 2 (1.9) yes, p-value 0.679
- Others: 5 (2.3) no, 1 (1) yes, 4 (3.7) yes, p-value 0.193

Total number of initial symptoms

- 0: 5 (2.3) no, 5 (4.8) yes, 0 (0) yes, p-value 0.014
- 1: 18 (8.5) no, 10 (9.5) yes, 8 (7.4) yes
- 2: 4 (1.9) no, 3 (2.9) yes, 1 (0.9) yes
- 3: 14 (6.6) no, 10 (9.5) yes, 4 (3.7) yes
- 4: 17 (8) no, 11 (10.5) yes, 6 (5.6) yes
- 5: 13 (6.1) no, 5 (4.8) yes, 8 (7.4) yes
- ⩾6: 142 (66.7) no, 61 (58.1) yes, 81 (75) yes

Data are presented as n, or n (%).

§Respondents who reported persistent symptoms and respondents who reported no persistent symptoms were compared using the chi-square test or Fisher’s exact test for categorical variables and one-way ANOVA for continuous variables. p-values < 0.05 indicate significant differences.

Table 2. COVID-19 diagnosis and management among respondents.

| Diagnosis                        | Total (N=213) (%) | Return to baseline health | p-value |
|----------------------------------|------------------|---------------------------|---------|
|                                  | No (N=61) (%)    | Yes (N=152) (%)           |         |
| Throat swab                      | 65 (30.5)        | 20 (32.8)                 | 45 (29.6)| 0.777 |
| Nasopharyngeal swab              | 137 (64.3)       | 38 (62.3)                 | 99 (65.1)|          |
| Through a physician (no investigation) | 11 (5.2)    | 3 (4.9)                   | 8 (5.3)  |          |
| Management                       |                  |                           |         |
| Advice from MOH hotline          | 157 (73.7)       | 50 (82%)                  | 107 (70.4)| 0.083 |
| Outpatient care                  | 127 (59.6)       | 35 (67.4)                 | 92 (60.5)| 0.672 |
| Hospital admission               | 18 (8.5)         | 5 (8.2)                   | 13 (8.6) | 0.933 |
| ICU admission                    | 4 (1.9)          | 4 (1.9)                   | 0 (0)    | 0.001 |
| Required oxygen therapy          | 31 (14.6)        | 14 (23)                   | 17 (11.2)| 0.028 |

ICU: intensive care unit; MOH: Ministry of Health.
Three months or more after a COVID-19 diagnosis, almost half of the respondents, 109 (51.2%), had residual symptoms. The five most reported persistent symptoms were fatigue 29 (13.6%), altered sense of smell 27 (12.7%), muscle aches 22 (10.3%), headache 21 (9.9%), and body aches 18 (8.5%). Figure 1 shows symptoms at diagnosis and persistent symptoms beyond 3 months of COVID-19 diagnosis.

When questioned regarding the return to the usual state of health, 152 (71.4%) answered in the affirmative. Of the four predictor variables for the delayed return to the usual state of health, only one was statistically significant: the total number of chronic medical conditions (Table 3).

**Table 3.** Logistic regression for predicting the likelihood of not returning to baseline health based on gender, age, the total number of chronic medical conditions, and the total number of symptoms at disease onset.

|                  | B   | SE   | Wald | Df | Sig  | Exp(B) | 95% CI for Exp(B) |
|------------------|-----|------|------|----|------|--------|-------------------|
| Gender           | 0.068 | 0.373 | 0.033 | 1 | 0.855 | 1.071 | 0.515 – 2.225     |
| Age              | 0.082 | 0.152 | 0.290 | 1 | 0.590 | 1.085 | 0.806 – 1.462     |
| Total number of  | −0.286 | 0.147 | 3.765 | 1 | 0.052 | 0.751 | 0.563 – 1.003     |
| chronic medical  |      |      |      |    |      |        |                   |
| conditions       |      |      |      |    |      |        |                   |
| Total number of  | −0.042 | 0.026 | 2.614 | 1 | 0.106 | 0.959 | 0.911 – 1.009     |
| symptoms at     |      |      |      |    |      |        |                   |
| disease onset    |      |      |      |    |      |        |                   |
| Constant         | 1.295 | 0.420 | 9.496 | 1 | 0.002 | 3.652 |                   |

**Discussion**

The long-lasting effects of COVID-19 are increasingly recognised. This cross-sectional study found that 5 out of 10 COVID-19 survivors experienced persistent symptoms 3 months beyond the initial disease onset, and 3 out of 10 reported a delayed return to the usual state of health. In our study, 109 (51.2%) had residual symptoms. Other studies
that sampled a similar population of hospitalised and non-hospitalised COVID-19 survivors and used 3 months as a cut-off point for defining long COVID have found similar percentages of 51.4% and 53.1%. On the other hand, a higher percentage of persistent symptoms, 67% and 93%, were described in cohorts of post-hospitalised patients. A recent meta-analysis has shown that there is a disease burden in the paediatric population, with a reported prevalence of 25.24%.

A recent scoping review has reported more than 100 persistent SARS-CoV-2 symptoms pooled from 50 studies. In the review, the significant variability in the prevalence of persistent symptoms among studies was speculated to be related to unknown cohort-specific factors. Fatigue, lost or altered sense of smell, muscle aches, headache, and body aches are the most frequently reported symptoms in our study. A living systematic review identified the following persistent symptoms 12 weeks or more post-COVID-19 as the most common symptoms reported: weakness (41%), general malaise (33%), fatigue (31%), concentration impairment (26%), and breathlessness (25%) as the most common symptoms reported. However, more than half of the studies included in the review (67%) were cohorts of post-discharge hospitalised patients.

Fatigue is the most frequently reported residual symptom in our study. Similarly, in several studies with similar follow-up duration, fatigue was described among the most common residual symptoms of COVID-19. Fatigue is also among the most frequent symptoms described in follow-ups extending beyond 6 months. Loss or altered sense of smell is the second most reported symptom experienced by 12.7% of the respondents. Other studies have reported similar results of 12% and 14.7%. One study reported a higher percentage (45%) when objective tests were used to detect hyposmia/anosmia; however, self-reported hyposmia/anosmia was lower (17%) for the same patients.

Morbidity persists with 28.6% of the respondents attesting not returning to their usual state of health. Townsend et al. reported a higher percentage of 62% when patients were followed up at a median of 75 days after diagnosis; however, 48% of the cohort were hospitalised (26% of which were in the intensive care unit). The number of comorbid conditions was a statistically significant variable when assessing the return to the usual state of health. Being overweight, in particular, was associated with a delayed return to the usual state of health (p = 0.021). Tenforde et al. also reported that obesity was associated with more than twofold odds of not returning to usual health; however, the median interval from diagnosis to interview was 16 days in their study.

Our study is novel in characterising persistent COVID-19 symptoms in hospitalised and home-isolated patients; thus, survivors with variable disease severity were included. However, a limitation of this study is the sample size of the pilot study (N=14, less than 10% of the projected sample size), and the small subgroups; hence, our findings should be confirmed in a larger cohort. Another limitation is the self-report nature of the study, as well as the inherent limitations of surveys. Therefore, studies supplemented with clinical assessment will be of value, in addition to patient-reported outcomes.

Conclusion

In conclusion, our study presents evidence supporting the emerging literature on the persistence of symptoms among COVID-19 survivors. In our cohort, 5 out of 10 COVID-19 survivors experienced persistent symptoms 3 months after the initial disease onset, and 3 out of 10 reported a delay in return to the usual state of health. Given the disease burden, priorities for the detection, management, and rehabilitation of this condition are urgently needed. In addition, due to the various possible persistent symptoms, multidisciplinary collaborative care, including primary healthcare providers, specialists, and occupational medicine, is required. Finally, the control of acute COVID-19 infection rates will ultimately reduce the prevalence of its post-acute sequelae.

Acknowledgements

The authors acknowledge the support of the Deanship of Scientific Research at the University of Ha’il, Saudi Arabia. They also extend their gratitude to all study participants and healthcare workers affected by the COVID-19 pandemic.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval for this study was obtained from the Research Ethics Committee at the University of Ha’il (Reference Number 00127/CM-UOH.04/20).

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the Deanship of Scientific Research at the University of Ha’il, Saudi Arabia, through project number: COVID-1915.

Informed consent

Written informed consent was obtained from all participants before the study.

ORCID iD

Hend M Alkwai https://orcid.org/0000-0001-6396-9263
Supplemental material

Supplemental material for this article is available online.

References

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard, https://covid19.who.int/ (2022, accessed January 17, 2022).
2. Perego E, Callard F, Stras L, et al. Why the patient-made term ‘long covid’ is needed. *Wellcome Open Research* 2020; 5: 224.
3. Callard F and Perego E. How and why patients made long covid. *Soc Sci Med* 2020; 268: 113426.
4. Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-Haulers. *J Med Virol* 2020; 93: 2555–2556.
5. Marshall M. The lasting misery of coronavirus long-haulers. *Nature* 2020; 585(7825): 339–341.
6. Kalter L. Fauci introduces new acronym for long COVID at White House briefing, https://www.medscape.com/viewarticle/946419 (2021, accessed 23 November 2021).
7. Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining long COVID: striking differences across literature, electronic health records, and patient-reported information. *MedRxiv* 2021; 3: 21253896.
8. NICE. Covid-19 rapid guideline: managing the long-term effects of covid-19, https://www.nice.org.uk/guidance/ng188/chapter/4-Planning-care (accessed 1 November 2021).
9. Greenhalgh T, Knight M, A’Court C, et al. Management of post-COVID-19 syndrome in Saudi Arabia. *Cureus* 2021; 13(9): e17787.
10. Brown DA and O’Brien KK. Conceptualising long COVID as an episodic health condition. *BMJ Glob Health* 2021; 6(9): e007004.
11. Hayes LD, Ingram J and Sculthorpe NF. More than 100 persistent symptoms of SARS-CoV-2 (Long COVID): a scoping review. *Front Med* 2021; 8: 750378.
12. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. *BMJ Glob Health* 2021; 6(9): e005427.
13. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nature Med* 2020; 26: 1017–1032.
14. Mahmoud MH, Alghamdi FA, Alghamdi GA, et al. Study of post-COVID-19 syndrome in Saudi Arabia. *Careus* 2021; 13(9): e17787.
15. Alharthy A, Abuhamdah M, Balhamar A, et al. Residual lung injury in patients recovering from COVID-19 critical illness. *J Ultrasound Med* 2021; 40(9): 1823–1838.
16. Abu-Hammad O, Alnazzawi A, Bakhair H, et al. COVID-19 infection in academic dental hospital personnel: a cross-sectional survey in Saudi Arabia. *Int J Environ Res Public Health* 2021; 18: 10911.
17. Alsofayan YM, Althunayyan SM, Khan AA, et al. Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study. *J Infect Public Health* 2020; 13(7): 920–925.
18. Townsend L, Dowds J, O’Brien K, et al. Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity. *Ann Am Thorac Soc* 2021; 18: 997–1003.
19. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID–19 in a multistate health care systems network — United States, March-June 2020. *Morbid Mortal Weekly Rep* 2020; 69: 993–998.
20. Cellai M and O’Keefe JB. Characterisation of prolonged COVID-19 symptoms in an outpatient telemedicine clinic. *Open Forum Infect Dis* 2020; 7: ofaa420.
21. Katz JN, Chang LC, Sangha O, et al. Can comorbidity be measured by questionnaire rather than medical record review. *Med Care* 1996; 34(1): 73–84.
22. Venturelli S, Benatti SV, Casati M, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. *Epidemiol Infect* 2021; 149: e32.
23. Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe islands: a longitudinal study among non-hospitalised patients. *Clin Infect Dis* 2020; 73: e4058–e4063.
24. Stavem K, Ghanima W, Olsen MK, et al. Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax* 2021; 76(4): 405–407.
25. Sigfrid L, Drake TM, Pauley E, et al. Long covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. *Lancet Reg Health Eur* 2021; 8: 100186.
26. Lopez-Leon S, Wegman-Ostrosky T, Ayuso Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. *Sci Rep* 2022; 12: 995020220623.
27. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* 2021; 27(1): 89–95.
28. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalisation for COVID-19. *J Infect* 2020; 81: e4–e6.
29. Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. *Thorax* 2021; 76(4): 399–401.
30. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. *JAMA Netw Open* 2021; 4: e210830.
31. Parente-Arias P, Barreira-Fernandez P, Quintana-Sanjuas A, et al. Recovery rate and factors associated with smell and taste disruption in patients with coronavirus disease 2019. *Am J Otolaryngol* 2021; 42(5): 102648–102648.
32. Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID-19: a prospective observational cohort study. *Eur J Neurol* 2021; 28(10): 3348–3359.